RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail therapy takes on tough lymphoma
Disease control Recruiting nowThis phase 2 trial is testing whether combining an immunotherapy drug (anti-PD-1) with two chemotherapy-like drugs (lenalidomide and azacitidine) can shrink tumors in people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. About 31 participa…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill combo targets tough lymphoma
Disease control Recruiting nowThis phase 2 trial tests two oral drugs, SHR-0302 and SHR-2554, in about 25 people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The drugs work by blocking specific proteins that help cancer grow. The study aims to see if the combination …
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New oral cancer drug enters first human safety trial
Disease control Recruiting nowThis early-stage study tests a new oral drug, AXT-1003, in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug shr…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Axter Therapeutics (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for rare blood cancer: phase 3 trial of XNW5004 launches
Disease control Recruiting nowThis Phase 3 trial tests whether the experimental drug XNW5004 can help people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. About 120 participants will receive either XNW5004 or the existing drug chidamide. The main goal is to see if…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for tough lymphoma: phase 3 trial pits SHR2554 against standard drug
Disease control Recruiting nowThis phase 3 trial compares a new drug called SHR2554 to an existing drug, chidamide, in 130 people with a rare type of lymphoma (PTCL) that has come back or not responded to at least one prior treatment. The main goal is to see if SHR2554 can delay cancer growth better than chid…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental CAR T-Cell therapy takes on tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called MB-105 for people with a type of blood cancer called T-cell lymphoma that has come back or not responded to standard treatments. MB-105 is made from the patient's own immune cells, which are modified to better recognize and attack cancer ce…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC